Vaxcyte closes stock and convertible note offerings

Vaxcyte said the concurrent equity and debt offerings closed on Oct. 9. The company said it sold 7,412,500 shares, pre-funded warrants for 400,000 shares and $500 million of 1.50% convertible senior notes due 2032, with over-allotment options exercised in full.